Latest Conference Articles

A study at AAAAI 2025 found that monitoring transepidermal water loss during oral food challenges reduced anaphylaxis rates and epinephrine use in children.

A study suggests the prevalence of Legionella may explain why children with seasonal allergic rhinitis vs perennial allergic rhinitis have more severe symptoms.

Participants in a phase 3 OLE had a mean monthly attack rate of 0.08.

Mepolizumab led to greater symptom score improvements than omalizumab in severe CRSwNP, though both biologics showed significant nasal polyp reduction.

Sebetralstat has a PDUFA date of June 12, 2025, for treating HAE in patients 12 years and older.

A new study presented at AAAAI 2025 linked pediatric obesity to a greater risk of developing allergic rhinitis, with a 1.24x increased risk at 1 year.

Three subgroup analyses of the phase 3 NAVIGATOR study are set to be presented at the AAAAI/WAO Joint Congress.

Phase 3 ANCHOR-1/2 data support depemokimab as a twice-yearly treatment for CRSwNP, effectively reducing blood eosinophil counts over 52 weeks.

A real-world analysis found mepolizumab significantly improved symptoms in CRSwNP patients, reducing SNOT-22 scores, oral corticosteroid use, and surgery rates.

Five years after peanut oral immunotherapy, children showed lower allergen-specific IgE and greater IgG4 levels than placebo, indicating sustained immune tolerance.

These phase 3 findings from the INTEGUMENT-PED clinical trial highlight the efficacy and safety of roflumilast cream 0.05% for pediatric patients with atopic dermatitis.

Phase 3 WAYPOINT trial shows tezepelumab significantly reduces nasal polyp severity, congestion, and surgery needed in severe chronic rhinosinusitis with nasal polyp.

A meta-analysis found oral immunotherapy improves health-related quality of life post-food allergy treatment, but benefits during treatment remain unclear.

A study analyzed hypersensitivity reactions to biologics for atopic diseases, highlighting reaction types, severity, and biologic discontinuation rates.

In new data to be presented at AAAAI, the therapy was well-tolerated in people as young as 2 years old.

By week 52, remibrutinib and placebo-to-remibrutinib groups had similar levels of urticaria control.

Data from 3 pooled phase 3 studies in children, adolescents, and adults will be presented at the AAAI/WAO Joint Congress.

A study found many patients with chronic spontaneous urticaria need add-on or higher-dose therapies, revealing gaps in treatment. Findings will be presented at AAAAI 2025.

At week 12, a higher proportion of participants on rilzabrutinib 1200mg a day (60.9%) achieved AAS7 scores of 0 than placebo-treated participants (30.8%).

Infants who develop atopic dermatitis show early cheek skin barrier dysfunction with delayed FLG processing, low ceramides, and high IL-18. The study will be presented at AAAAI 2025.

At 6 months, baseline monthly rates of 0.45 for mild, 1.54 for moderate, and 0.14 for severe attacks were reduced to 0.10, 0.08, and 0.00, respectively.

Bernstein discussed recent and upcoming research and management of angioedema in patients with urticaria.

Children with severe atopic dermatitis saw > 5 percentile height gains after 16 weeks of dupilumab, per a study to be presented at AAAAI 2025.

Around half of participants had insufficient vitamin D levels.

A study found the Skin Barrier Meter accurately measures skin barrier function in children with atopic dermatitis, offering a fast, non-invasive assessment within 5 seconds.

Fifteen of 16 patients with chronic ulcers in a small study had positive patch test to common wound care products.

A study found distinct DNA methylation patterns at birth linked to early-onset atopic dermatitis by age 2. Findings will be presented at AAAAI 2025.

New 2-year data from the BE HEARD program shed further light on the role bimekizumab in treatment algorithms for HS.